Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
J.B.CHEMICALS ACTAVIS |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
J.B.CHEMICALS Mar-23 |
ACTAVIS Dec-18 |
J.B.CHEMICALS/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,150 | 16,159 | - | |
Low | Rs | 1,339 | 10,840 | - | |
Sales per share (Unadj.) | Rs | 407.0 | 3,963.8 | - | |
Earnings per share (Unadj.) | Rs | 53.0 | -1,276.8 | - | |
Cash flow per share (Unadj.) | Rs | 67.8 | 417.7 | - | |
Dividends per share (Unadj.) | Rs | 8.88 | 0 | - | |
Avg Dividend yield | % | 0.5 | 0 | - | |
Book value per share (Unadj.) | Rs | 304.8 | 16,349.0 | - | |
Shares outstanding (eoy) | m | 77.38 | 332.60 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 4.3 | 3.4 | 125.9% | |
Avg P/E ratio | x | 32.9 | -10.6 | -311.4% | |
P/CF ratio (eoy) | x | 25.7 | 32.3 | 79.6% | |
Price / Book Value ratio | x | 5.7 | 0.8 | 693.1% | |
Dividend payout | % | 16.7 | 0 | - | |
Avg Mkt Cap | Rs m | 134,983 | 4,489,898 | 3.0% | |
No. of employees | `000 | NA | 16.9 | 0.0% | |
Total wages/salary | Rs m | 5,435 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 78,010.2 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | -25,127.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 31,493 | 1,318,372 | 2.4% | |
Other income | Rs m | 99 | 25,212 | 0.4% | |
Total revenues | Rs m | 31,592 | 1,343,584 | 2.4% | |
Gross profit | Rs m | 6,958 | 34,548 | 20.1% | |
Depreciation | Rs m | 1,144 | 563,576 | 0.2% | |
Interest | Rs m | 361 | 76,078 | 0.5% | |
Profit before tax | Rs m | 5,552 | -579,893 | -1.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 147,896 | 0.0% | |
Tax | Rs m | 1,452 | -7,349 | -19.8% | |
Profit after tax | Rs m | 4,100 | -424,648 | -1.0% | |
Gross profit margin | % | 22.1 | 2.6 | 843.1% | |
Effective tax rate | % | 26.2 | 1.3 | 2,064.0% | |
Net profit margin | % | 13.0 | -32.2 | -40.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 15,993 | 540,727 | 3.0% | |
Current liabilities | Rs m | 6,257 | 478,345 | 1.3% | |
Net working cap to sales | % | 30.9 | 4.7 | 653.3% | |
Current ratio | x | 2.6 | 1.1 | 226.1% | |
Inventory Days | Days | 85 | 20 | 434.9% | |
Debtors Days | Days | 667 | 66 | 1,006.4% | |
Net fixed assets | Rs m | 24,988 | 149,232 | 16.7% | |
Share capital | Rs m | 155 | 0 | - | |
Net worth | Rs m | 23,587 | 5,437,670 | 0.4% | |
Long term debt | Rs m | 3,832 | 1,914,801 | 0.2% | |
Total assets | Rs m | 40,981 | 8,500,316 | 0.5% | |
Interest coverage | x | 16.4 | -6.6 | -247.7% | |
Debt to equity ratio | x | 0.2 | 0.4 | 46.1% | |
Sales to assets ratio | x | 0.8 | 0.2 | 495.5% | |
Return on assets | % | 10.9 | -4.1 | -265.4% | |
Return on equity | % | 17.4 | -7.8 | -222.6% | |
Return on capital | % | 21.6 | -4.8 | -445.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 6,256 | 471,005 | 1.3% | |
From Investments | Rs m | -9,618 | 258,756 | -3.7% | |
From Financial Activity | Rs m | 3,565 | -808,385 | -0.4% | |
Net Cashflow | Rs m | 204 | -78,232 | -0.3% |
Compare J.B.CHEMICALS With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare J.B.CHEMICALS With: ASTRAZENECA PHARMA SUPRIYA LIFESCIENCE PANCHSHEEL ORG VILIN BIO MED BETA DRUGS
It was indeed a volatile trading session for Indian share markets today. Benchmark indices swung between gains and losses throughout the day.